Creative Medical Technology Holdings, Inc.
CELZAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Roth Capital | maintain | Buy | Feb 25, 2022 |
Earnings History
Next report: Mar 19, 2027 · EPS est. $-0.24| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 6, 2026 | $-0.40 | $-0.24 | — | — |
| Aug 7, 2026 | $-0.41 | $-0.39 | — | — |
| May 8, 2026 | $-0.38 | $-0.39 | — | — |
| Mar 20, 2026 | $-0.80 | $-0.37 | $3.0K | $3.0K |
| Nov 7, 2025 | $-0.48 | $-0.48 | — | — |
| Aug 8, 2025 | $-0.48 | $-0.63 | — | — |
| May 9, 2025 | $-0.83 | $-0.52 | $3.0K | — |
| Mar 14, 2025 | $-1.12 | $-0.63 | $3.0K | — |
News
PHOENIX, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine technologies, today highlighted additional clinical and laboratory findings for Ultrasome™, its investigational cell-free regenerative medicine platform, following a presentation at the Annual Meeting of Experts in Cell and Gene Therapy held October 10, 2026, in Lima, Peru. The study eval…
Grifols (NASDAQ: GRFS - Get Free Report) and Creative Medical Technology (NASDAQ: CELZ - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations. Earnings and Valuation This table compares Grifols and
argenex (NASDAQ: ARGX - Get Free Report) and Creative Medical Technology (NASDAQ: CELZ - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends. Analyst Ratings This is a breakdown of current
PHOENIX, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced the filing of a new U.S. provisional patent application designed to expand intellectual property protection surrounding Ultrasome™, the Company's proprietary cell-free regenerative medicine platform.
Creative Medical Technology (NASDAQ: CELZ - Get Free Report) and CRISPR Therapeutics (NASDAQ: CRSP - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings. Institutional and Insider Ownership 1.4% of Creative
All patients enrolled and treated across original and FDA-cleared expansion cohorts Positive safety and early efficacy signals continue to support late-stage development planning for Olastrocel in chronic lower back pain With enrollment and treatment completed, ADAPT-related clinical execution expenses are expected to decrease as the program transitions into follow-up, data maturation and regulatory planning Company believes reduced enrollment- and treatment-related expenditures should help pres…